Artiva Biotherapeutics, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
ARTV Nasdaq 2836 www.artivabio.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Artiva Biotherapeutics, Inc.

Artiva Biotherapeutics Reports First Quarter 2025 Financial Results, Recent Business Highlights - May 8th, 2025 12:00 pm
Artiva Biotherapeutics to Present Longer-term Phase 1/2 Data for AlloNK® in Combination with Rituximab in Patients with B-cell-Non-Hodgkin Lymphoma at the ASGCT 28th Annual Meeting - Apr 28th, 2025 8:35 pm
Artiva Biotherapeutics Appoints Subhashis Banerjee, M.D., as Chief Medical Officer - Apr 8th, 2025 8:05 pm
Artiva Biotherapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference - Mar 31st, 2025 8:05 pm
Artiva Biotherapeutics Reports Full Year 2024 Financial Results and Recent Business Highlights - Mar 24th, 2025 8:05 pm
Artiva Biotherapeutics to Participate in the TD Cowen 45th Annual Health Care Conference - Feb 20th, 2025 9:05 pm
Artiva Biotherapeutics Expands Board of Directors with Appointment of Dan Baker, M.D. - Jan 29th, 2025 9:05 pm
Artiva Biotherapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights - Nov 12th, 2024 9:05 pm
Artiva Biotherapeutics to Participate in the Jefferies London Healthcare Conference - Nov 11th, 2024 9:05 pm
Artiva Biotherapeutics Appoints Alison Moore, Ph.D., to Its Board of Directors - Oct 22nd, 2024 8:05 pm
Artiva Biotherapeutics to Participate in the 2024 Cantor Fitzgerald Global Healthcare Conference - Sep 10th, 2024 8:05 pm
Artiva Biotherapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights - Aug 29th, 2024 8:05 pm
Is Artiva Biotherapeutics (NASDAQ:ARTV) In A Good Position To Deliver On Growth Plans? - Jul 20th, 2024 1:19 pm
Artiva Biotherapeutics Announces Pricing of Upsized $167.0 Million Initial Public Offering - Jul 18th, 2024 11:08 pm